Found: 81
Select item for more details and to access through your institution.
Everolimus.
- Published in:
- 2009
- By:
- Publication type:
- journal article
High-Dose Recombinant Interleukin-2 Alone: A Regimen With Limited Activity in the Treatment of Advanced Renal Cell Carcinoma.
- Published in:
- JNCI: Journal of the National Cancer Institute, 1990, v. 82, n. 14, p. 1202, doi. 10.1093/jnci/82.14.1202
- By:
- Publication type:
- Article
Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
- Published in:
- BJU International, 2010, v. 106, n. 6, p. 772, doi. 10.1111/j.1464-410X.2010.09218.x
- By:
- Publication type:
- Article
An Evidence-based Staging System for Cutaneous Melanoma.
- Published in:
- CA: A Cancer Journal for Clinicians, 2004, v. 54, n. 3, p. 131, doi. 10.3322/canjclin.54.3.131
- By:
- Publication type:
- Article
Cytokine therapy in melanoma.
- Published in:
- Journal of Cutaneous Pathology, 2010, v. 37, p. 60, doi. 10.1111/j.1600-0560.2010.01507.x
- By:
- Publication type:
- Article
Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer.
- Published in:
- Clinical Genitourinary Cancer, 2022, v. 20, n. 6, p. 553, doi. 10.1016/j.clgc.2022.08.005
- By:
- Publication type:
- Article
Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study.
- Published in:
- Clinical Genitourinary Cancer, 2021, v. 19, n. 5, p. 468.e1, doi. 10.1016/j.clgc.2021.03.018
- By:
- Publication type:
- Article
Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma.
- Published in:
- Clinical Genitourinary Cancer, 2021, v. 19, n. 5, p. e306, doi. 10.1016/j.clgc.2021.03.019
- By:
- Publication type:
- Article
Societal preferences for adjuvant melanoma health states: UK and Australia.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents—post hoc analyses of the ASCEND-ND and ASCEND-D trials.
- Published in:
- Nephrology Dialysis Transplantation, 2023, v. 38, n. 8, p. 1890, doi. 10.1093/ndt/gfac342
- By:
- Publication type:
- Article
Symptomatic Exacerbation of Crohn Disease after Treatment with High--Dose Interleukin--2.
- Published in:
- Annals of Internal Medicine, 1993, v. 118, n. 8, p. 617, doi. 10.7326/0003-4819-118-8-199304150-00007
- By:
- Publication type:
- Article
Nosocomial sepsis associated with interleukin-2.
- Published in:
- 1990
- By:
- Publication type:
- journal article
Interleukin-12, a New Anti-Tumor Cytokine.
- Published in:
- International Journal of Immunopathology & Pharmacology, 1998, v. 11, n. 3, p. 109, doi. 10.1177/039463209801100301
- By:
- Publication type:
- Article
A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 1019, doi. 10.1007/s10637-020-01058-2
- By:
- Publication type:
- Article
Genetic Associations with Indoor Tanning Addiction among non-Hispanic White Young Adult Women.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression.
- Published in:
- PLoS ONE, 2011, v. 6, n. 4, p. 1, doi. 10.1371/journal.pone.0019144
- By:
- Publication type:
- Article
Prognostic and Predictive Markers for the New Immunotherapies.
- Published in:
- Oncology (08909091), 2014, p. 1
- By:
- Publication type:
- Article
The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management.
- Published in:
- JNCI Cancer Spectrum, 2018, v. 2, n. 3, p. 1, doi. 10.1093/jncics/pky021
- By:
- Publication type:
- Article
Book Review.
- Published in:
- 1999
- By:
- Publication type:
- Book Review
Correction: Zhang et al. Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. Cancers 2021, 13 , 6109.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Transcriptional Profiling of Malignant Melanoma Reveals Novel and Potentially Targetable Gene Fusions.
- Published in:
- Cancers, 2022, v. 14, n. 6, p. 1505, doi. 10.3390/cancers14061505
- By:
- Publication type:
- Article
Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis.
- Published in:
- Cancers, 2021, v. 13, n. 23, p. 6109, doi. 10.3390/cancers13236109
- By:
- Publication type:
- Article
Incidence and Durability of SARS-CoV-2 Antibodies in Patients with Cancer and Health Care Workers following the First Wave of the Pandemic.
- Published in:
- Journal of Oncology, 2022, p. 1, doi. 10.1155/2022/8798306
- By:
- Publication type:
- Article
Update on the DREAMseq Trial in Melanoma.
- Published in:
- Clinical Advances in Hematology & Oncology, 2023, v. 21, n. 6, p. 304
- By:
- Publication type:
- Article
Adoptive immunotherapy for nonsmall cell lung carcinoma: A fourth treatment modality, complicated radiation sensitizer, or none of the above.
- Published in:
- Cancer (0008543X), 1996, v. 78, n. 2, p. 195, doi. 10.1002/(SICI)1097-0142(19960715)78:2<195::AID-CNCR1>3.0.CO;2-L
- By:
- Publication type:
- Article
Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma.
- Published in:
- BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-10708-6
- By:
- Publication type:
- Article
High frequency of brain metastases after adjuvant therapy for high-risk melanoma.
- Published in:
- Cancer Medicine, 2017, v. 6, n. 11, p. 2576, doi. 10.1002/cam4.1223
- By:
- Publication type:
- Article
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status.
- Published in:
- Cancer Medicine, 2017, v. 6, n. 8, p. 1904, doi. 10.1002/cam4.1140
- By:
- Publication type:
- Article
Volume of Disease as a Predictor for Clinical Outcomes in Patients With Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Therapy.
- Published in:
- Frontiers in Oncology, 2022, v. 11, p. 1, doi. 10.3389/fonc.2021.794615
- By:
- Publication type:
- Article
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204).
- Published in:
- Neuro-Oncology, 2021, v. 23, n. 11, p. 1961, doi. 10.1093/neuonc/noab094
- By:
- Publication type:
- Article
Management of metastatic cutaneous melanoma: updates in clinical practice.
- Published in:
- Therapeutic Advances in Medical Oncology, 2019, v. 11, p. 1, doi. 10.1177/1758835919851663
- By:
- Publication type:
- Article
Management of metastatic cutaneous melanoma: updates in clinical practice.
- Published in:
- Therapeutic Advances in Medical Oncology, 2019, v. 11, p. N.PAG, doi. 10.1177/1758835919851663
- By:
- Publication type:
- Article
Treatment of patients with metastatic renal cell cancer.
- Published in:
- Cancer (0008543X), 2006, v. 107, n. 10, p. 2375, doi. 10.1002/cncr.22260
- By:
- Publication type:
- Article
Multicenter Phase II trial of high‐dose imatinib mesylate in metastatic melanomaPresented in part as a poster (abstract 2865) at the Annual Meeting of the American Society of Clinical Oncology; Chicago, Illinois, May 31–June 3, 2003.: Significant toxicity with no clinical efficacy
- Published in:
- Cancer (0008543X), 2006, v. 106, n. 9, p. 2005
- By:
- Publication type:
- Article
A new American Joint Committee on Cancer staging system for cutaneous melanoma.
- Published in:
- 2000
- By:
- Publication type:
- journal article
Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor-Induced Enteritis.
- Published in:
- ACG Case Reports Journal, 2018, v. 5, p. 1, doi. 10.14309/crj.2018.17
- By:
- Publication type:
- Article
BDS AS A THREAT TO ACADEMIC FREEDOM AND CAMPUS FREE SPEECH IN THE UNITED STATES.
- Published in:
- Michigan State International Law Review, 2021, v. 29, n. 2, p. 213
- By:
- Publication type:
- Article
Correlates of Sun Safety Practices in a Racially and Ethnically Diverse Sample of Adolescents: Implications for Skin Cancer Prevention Interventions.
- Published in:
- Pediatric Dermatology, 2015, v. 32, n. 6, p. e288, doi. 10.1111/pde.12642
- By:
- Publication type:
- Article
Long-Term Use of Nonsteroidal Anti-inflammatory Drugs Decreases the Risk of Cutaneous Melanoma: Results of a United States Case-Control Study.
- Published in:
- 2011
- By:
- Publication type:
- Case Study
The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Patient‐reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma.
- Published in:
- BJU International, 2020, v. 126, n. 1, p. 73, doi. 10.1111/bju.15058
- By:
- Publication type:
- Article
Everolimus: Emerging Evidence of its Therapeutic Impact in Patients with Advanced Renal Cell Carcinoma.
- Published in:
- Clinical Medicine Reviews in Oncology, 2010, n. 2, p. 99, doi. 10.4137/cmro.s3428
- By:
- Publication type:
- Article
What's new in melanoma? Combination!
- Published in:
- Journal of Translational Medicine, 2015, v. 13, n. 1, p. 1, doi. 10.1186/s12967-015-0582-1
- By:
- Publication type:
- Article
Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial.
- Published in:
- Journal of Translational Medicine, 2010, v. 8, p. 108, doi. 10.1186/1479-5876-8-108
- By:
- Publication type:
- Article
Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases.
- Published in:
- NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-023-00471-z
- By:
- Publication type:
- Article
Management of metastatic renal cell carcinoma in patients with poor prognosis.
- Published in:
- Cancer Management & Research, 2010, v. 2, p. 123
- By:
- Publication type:
- Article
What Is Optimal First-Line Treatment of Unresectable or Advanced BRAF-Mutant Melanoma?
- Published in:
- Clinical Advances in Hematology & Oncology, 2016, v. 14, n. 6, p. 417
- By:
- Publication type:
- Article
Immunotherapy or Molecularly Targeted Therapy: What Is the Best Initial Treatment for Stage IV BRAF-Mutant Melanoma?
- Published in:
- Clinical Advances in Hematology & Oncology, 2015, v. 13, n. 7, p. 1
- By:
- Publication type:
- Article
A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.
- Published in:
- 2019
- By:
- Publication type:
- journal article